This document is page 96 of a financial research report titled 'Cowen Collaborative Insights' dated February 25, 2019. It contains 'Figure 136 Cannabis Comp Table,' an appendix listing market data and valuations for various cannabis-related companies such as Aphria Inc, Aurora Cannabis Inc, and Level Brands Inc. The document bears a 'HOUSE_OVERSIGHT_024912' stamp, indicating it was part of a document production to the House Oversight Committee, likely obtained from the files of Michael Cella at Cowen.
This document is page 34 of a Cowen 'Collaborative Insights' market research report dated February 25, 2019. It analyzes the packaging and pricing of CBD gummy products from four different companies: CV Sciences, Green Roads, Highline Wellness, and cbdMD. The document bears a 'HOUSE_OVERSIGHT_024850' Bates stamp, indicating it was part of a document production to the House Oversight Committee, though the content appears to be standard equity research unrelated to criminal activity.
This document is page 31 of a 'Cowen Collaborative Insights' market research report dated February 25, 2019. It analyzes the pricing segments of various CBD capsule brands and presents demographic data (gender, age, income) regarding CBD capsule usage based on a January 2019 survey. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production to the House Oversight Committee, likely as part of a larger cache of financial or corporate records.
This document is page 26 of a market research report titled 'Cowen Collaborative Insights' dated February 25, 2019. It analyzes the CBD and Hemp industry through the lens of Instagram metrics (followers, posts, likes) for January 2019, comparing emerging brands like CBDFX and Lord Jones against established public companies. While the document bears a 'HOUSE_OVERSIGHT_024842' stamp, suggesting it was part of a document production for a congressional investigation (potentially related to financial probes involving Epstein or Deutsche Bank), the content itself is strictly commercial market analysis with no direct mention of Jeffrey Epstein.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity